How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey.
How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey.
复制标题
当前时代我们如何定义急性髓系白血病的完全缓解？
DOI：
10.1002/ajh.23497
复制
发表时间：
2013
影响因子：
12.8
通讯作者：
Ustun,Celalettin
中科院分区：
文献类型：
--
作者：
Burke,MichaelJ;Burns,Linda;Linden,MichaelA;Lindgren,Bruce;Verneris,MichaelR;Weisdorf,Daniel;Ustun,Celalettin
急性髓系白血病（AML）完全缓解（CR）的解释仍然是一个争论话题。 2003 年，国际工作组 (IWG) 发布了关于 AML 响应标准标准化的建议。[1]采用流式细胞术结合形态学缓解（< 5% 骨髓母细胞）和缺乏独特表型的方法。目前尚不清楚从业者是否仍在使用这些标记或已经开始将细胞遗传学/分子标记纳入他们的 CR 定义中。随着对可定义 CR 的 AML 细胞遗传学/分子变化的了解不断增加，[2, 3] 该信息可能已用于对治疗决策的缓解进行分类。为了解决这个问题，我们创建了一项电子调查，其中包含一些问题，以确定医生用于对 AML 中 CR 进行分类的标准以及这些标准如何影响治疗建议。
Interpretation of complete remission (CR) in acute myeloid leukemia (AML) remains a topic of debate. In 2003, the International Working Group (IWG) published recommendations for standardization of response criteria in AML.[1] The combination of morphologic remission (< 5% marrow blasts) and absence of a unique phenotype by flow cytometry was used. Whether practioners still use these or have begun to incorporate cytogenetic/molecular markers into their definition of CR is not known. With increasing knowledge of cytogenetic/molecular changes for AML that could define CR,[2, 3] this information may already be in use to classify remission for treatment decisions. To address this question, we created an electronic survey comprised of questions to identify criteria physicians use to classify CR in AML and how these influence treatment recommendations.